AAM Laments Price Negotiation Legislation Passing US Senate
‘Flawed’ Law Will ‘Further Frustrate Access’ To Generics And Biosimilars
The AAM has criticized the passage of the US Inflation Reduction Act though the country’s Senate, claiming that the legislation’s “flawed framework for government price setting” will chill generic and biosimilar development and will reduce patient access.
You may also be interested in...
AAM Names Teva’s Baeder Chair As It Kicks Off Annual Meeting
Christine Baeder has become chair of the AAM’s board, with the Teva executive welcomed to role as the US industry association kicked off its annual Access! conference in Orlando.
Leonard Resignation Leaves AAM Looking For New Leadership
Dan Leonard has announced his resignation as president and CEO of the US Association for Accessible Medicines. He will be replaced on an interim basis by the group’s vice president for sciences and regulatory affairs, David Gaugh.
AAM CEO Leonard Departs After Two Years, Creating Another Trade Group Searching For New Leader
David Gaugh, AAM’s executive VP of sciences and regulatory affairs, was named the interim CEO, making him the fourth person to run the association since February 2020.